Management of Neovascular AMD: New and Emerging Treatments for Optimal Disease Control is organized by Healio.
Release Date: October 31, 2023
Expiration Date: October 30, 2024
Activity Description:
The development and inclusion of anti-vascular endothelial growth factor (VEGF) therapies revolutionized the treatment of neovascular age-related macular degeneration (nAMD). Although these therapies have proven to be highly beneficial in arresting or reversing vision loss, the substantial number of nonresponders, together with the treatment burden associated with the need for frequent intravitreal injections, results in many patients failing to achieve optimal outcomes. Moreover, persistent disease activity and treatment adherence problems associated with standard-of-care anti-VEGF therapy can result in long-term vision deterioration in some patients. Thus, the search for improved therapies continues, leading to new and emerging treatment options, ranging from delivery systems that provide continuous dosing over extended periods to novel medications with new mechanisms of action that require fewer injections than traditional therapies. This educational activity has been designed to review the rationale for new therapies for nAMD, the clinical data supporting emerging therapies and novel approaches that may improve clinical outcomes in patients with this disorder, and the potential role of these new therapeutic strategies in the current treatment algorithm.
Educational Objectives:
Upon successful completion of this activity, participants should be better able to:
• Describe the current deficiencies and unmet needs in the treatment of nAMD.
• Assess how emerging therapies will address unmet needs associated with standard-of-care anti-vascular endothelial growth factor therapies in nAMD.
• Examine the latest clinical evidence on the safety and efficacy of therapies in late-stage development for nAMD.